Yamamoto Yohei, Uchiyama Hidetoshi, Oonuki Masahiro, Tsukuda Kazuki, Kazama Ai, Wada Yoshiki, Uchiyama Hiroki, Kikuchi Toru, Nishizawa Masato, Kudo Toshifumi
Division of Vascular Surgery, Department of Cardiovascular Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Department of Vascular Surgery, Tsuchiura Kyodo General Hospital, 4-1-1 Otsuno, Tsuchiura-shi, Ibaraki, 300-0028, Japan.
Surg Today. 2025 Feb;55(2):222-228. doi: 10.1007/s00595-024-02898-8. Epub 2024 Jul 17.
To report the outcomes of below-the-knee (BK) bypass surgery using heparin-bonded expanded polytetrafluoroethylene (ePTFE) grafts, performed in two centers since its launch in Japan.
We conducted a retrospective analysis of databases from two medical centers, evaluating 51 limbs in 42 consecutive patients with peripheral arterial disease (PAD), who underwent BK bypass surgery using heparin-bonded ePTFE grafts between October, 2013 and April, 2023.
Thirty-three limbs (64.7%) were classified as Rutherford category 4-6 and 33 limbs (64.7%) had a history of ipsilateral revascularization. Technical success was achieved in 98% of the patients. The 30 day mortality rate was 2.4% (n = 1) and the overall 30 day complication rate was 9.5% (n = 4). The median follow-up period was 38 (interquartile range 13-67) months. Three patients required major amputation and 14 died during follow-up. Primary patency rates at 1, 3, and 5 years were 67.8%, 57.5%, and 46.5%, respectively, while secondary patency rates for these periods were 84.6%, 70.0%, and 66.0%, respectively. Overall survival rates at 1, 3, and 5 years were 90.1%, 74.5%, and 70.9%, respectively.
BK bypass surgery using heparin-bonded ePTFE graft is a viable and durable option for patients with PAD, who are deemed unsuitable for autologous vein bypass surgery.
报告自肝素结合型膨体聚四氟乙烯(ePTFE)移植物在日本上市以来,两个中心开展的膝下(BK)旁路手术的结果。
我们对两个医疗中心的数据库进行了回顾性分析,评估了2013年10月至2023年4月期间连续42例接受外周动脉疾病(PAD)的患者使用肝素结合型ePTFE移植物进行BK旁路手术的51条肢体。
33条肢体(64.7%)被归类为卢瑟福分类4-6级,33条肢体(64.7%)有同侧血运重建史。98%的患者手术技术成功。30天死亡率为2.4%(n = 1),30天总体并发症发生率为9.5%(n = 4)。中位随访期为38(四分位间距13 - 67)个月。3例患者需要进行大截肢,14例在随访期间死亡。1年、3年和5年的原发性通畅率分别为67.8%、57.5%和46.5%,而这些时期的继发性通畅率分别为84.6%、70.0%和66.0%。1年、3年和5年的总体生存率分别为90.1%、74.5%和70.9%。
对于被认为不适合自体静脉旁路手术的PAD患者,使用肝素结合型ePTFE移植物进行BK旁路手术是一种可行且持久的选择。